AJ Bell's Russ Mould, Danni Hewson and Dan Coatsworth point out that Berkshire Hathaway has actually been whittling down its ...

The U.S. Food and Drug Administration on Friday warned patients and health care professionals not to use compounded drugs, ...

A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...

The world’s latest AI machine is powered by the success of two products: Nvidia’s chips and Novo Nordisk’s weight-loss drugs.

Stay ahead of the market with Seeking Alpha's Wall Street Week Ahead newsletter, previewing key events like elections, Fed meeting, earnings reports.

Charting, Price Performance, News & Related Contracts.

A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis ...

The company has invested over $100 million in the creation of this facility. Similarly, Novo Nordisk’s Global Business ...

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Novo Nordisk expects to file for regulatory approvals in the US and EU in the first half of 2025. The detailed results from ESSENCE will be presented at a scientific conference in 2024. Part 2 of the ...

OZEMPIC and other weight loss jabs have now been linked to ten deaths in the UK. There have also been 7,228 reports of illness associated with the drugs, citing nausea, vomiting and diarrhoea, ...